{"id": "article-17383_0", "title": "Almotriptan -- Continuing Education Activity", "content": "Almotriptan is a medication used in the management and treatment of acute migraines.\u00a0The medication is in the triptan 5-HT class of drugs.\u00a0Participating clinicians review the indications, actions, and contraindications for almotriptan as a valuable agent in treating and managing acute migraines.", "contents": "Almotriptan -- Continuing Education Activity. Almotriptan is a medication used in the management and treatment of acute migraines.\u00a0The medication is in the triptan 5-HT class of drugs.\u00a0Participating clinicians review the indications, actions, and contraindications for almotriptan as a valuable agent in treating and managing acute migraines."}
{"id": "article-17383_1", "title": "Almotriptan -- Continuing Education Activity", "content": "This activity highlights the mechanism of action, adverse effects, and vital factors such as dosing, pharmacodynamics, pharmacokinetics, monitoring, and relevant interactions pertinent for interprofessional team members in treating and caring for patients with acute migraines and related conditions. The interprofessional team, ranging from primary care clinicians and emergency clinicians to specialists, benefit from guideline-specific practices.", "contents": "Almotriptan -- Continuing Education Activity. This activity highlights the mechanism of action, adverse effects, and vital factors such as dosing, pharmacodynamics, pharmacokinetics, monitoring, and relevant interactions pertinent for interprofessional team members in treating and caring for patients with acute migraines and related conditions. The interprofessional team, ranging from primary care clinicians and emergency clinicians to specialists, benefit from guideline-specific practices."}
{"id": "article-17383_2", "title": "Almotriptan -- Continuing Education Activity", "content": "Objectives: Identify the indications for almotriptan use. Differentiate between various migraine types and accurately diagnose those suitable for almotriptan intervention, considering factors such as aura, frequency, and associated symptoms. Implement evidence-based guidelines in the use of almotriptan for acute migraine attacks, including dosage adjustments and appropriate timing of administration. Collaborate with the interprofessional team to coordinate a comprehensive approach to migraine management, especially in cases requiring a multidisciplinary perspective. Access free multiple choice questions on this topic.", "contents": "Almotriptan -- Continuing Education Activity. Objectives: Identify the indications for almotriptan use. Differentiate between various migraine types and accurately diagnose those suitable for almotriptan intervention, considering factors such as aura, frequency, and associated symptoms. Implement evidence-based guidelines in the use of almotriptan for acute migraine attacks, including dosage adjustments and appropriate timing of administration. Collaborate with the interprofessional team to coordinate a comprehensive approach to migraine management, especially in cases requiring a multidisciplinary perspective. Access free multiple choice questions on this topic."}
{"id": "article-17383_3", "title": "Almotriptan -- Indications", "content": "Almotriptan is the first FDA-approved drug to treat migraine\u00a0headaches in adults with or without an aura. [1] The drug is also\u00a0beneficial in adolescents with a history of a migraine that, when left untreated, lasts 4 hours or longer. Certain triptan medications, such as almotriptan and rizatriptan, are effective and safe for managing acute migraines and benign headaches in the pediatric population (less than 18 years of age). [2]", "contents": "Almotriptan -- Indications. Almotriptan is the first FDA-approved drug to treat migraine\u00a0headaches in adults with or without an aura. [1] The drug is also\u00a0beneficial in adolescents with a history of a migraine that, when left untreated, lasts 4 hours or longer. Certain triptan medications, such as almotriptan and rizatriptan, are effective and safe for managing acute migraines and benign headaches in the pediatric population (less than 18 years of age). [2]"}
{"id": "article-17383_4", "title": "Almotriptan -- Indications", "content": "Almotriptan has approval for use as monotherapy and in conjunction with migraine-abortive medications such as non-steroidal anti-inflammatory drugs (eg, aceclofenac). [3] Oral formulations are the most common. [4] Almotriptan is a white, coated circular tablet and requires a prescription from a registered\u00a0clinician in the United States. [5]", "contents": "Almotriptan -- Indications. Almotriptan has approval for use as monotherapy and in conjunction with migraine-abortive medications such as non-steroidal anti-inflammatory drugs (eg, aceclofenac). [3] Oral formulations are the most common. [4] Almotriptan is a white, coated circular tablet and requires a prescription from a registered\u00a0clinician in the United States. [5]"}
{"id": "article-17383_5", "title": "Almotriptan -- Indications", "content": "A randomized, double-blind study by Pascual J. et al examined the therapeutic efficacy and side effect profile of almotriptan.\u00a0The drug\u00a0was given as a single dose of 6.25 mg or 12.5 mg and\u00a0compared with placebo in patients with\u00a03 consecutive migraine episodes of moderate to severe presentation. Seven hundred twenty-two patients completed the study out of 1013 initially enrolled. Almotriptan was superior to placebo in reducing the migraine pain from moderate-severe to mild-no pain at 2 hours after the dose, ie, 60% (6.25 mg) and 70% (12.5 mg) vs. 38% (placebo). There appeared to be no clinically significant differences in side effects between the almotriptan-treated patients compared with the placebo. The study recommends a dose of 12.5 mg to treat migraines because the risk-to-benefit ratio is optimal at this dose. [6]", "contents": "Almotriptan -- Indications. A randomized, double-blind study by Pascual J. et al examined the therapeutic efficacy and side effect profile of almotriptan.\u00a0The drug\u00a0was given as a single dose of 6.25 mg or 12.5 mg and\u00a0compared with placebo in patients with\u00a03 consecutive migraine episodes of moderate to severe presentation. Seven hundred twenty-two patients completed the study out of 1013 initially enrolled. Almotriptan was superior to placebo in reducing the migraine pain from moderate-severe to mild-no pain at 2 hours after the dose, ie, 60% (6.25 mg) and 70% (12.5 mg) vs. 38% (placebo). There appeared to be no clinically significant differences in side effects between the almotriptan-treated patients compared with the placebo. The study recommends a dose of 12.5 mg to treat migraines because the risk-to-benefit ratio is optimal at this dose. [6]"}
{"id": "article-17383_6", "title": "Almotriptan -- Indications", "content": "A randomized double-blinded study by Dalof C. et al examined the therapeutic efficacy and side effect profile of almotriptan.\u00a0The triptan was given as a single dose of 2 mg, 6.25 mg, 12.5 mg, or 25 mg, and it was compared with a placebo in patients with moderate to severe migraine pain intensity. Seven hundred forty-two patients completed the study out of 903 initially enrolled. Almotriptan was superior to placebo in reducing the migraine pain at doses above 2 mg at 2 hours after dose, ie, 30% (2 mg), 56.3% (6.25 mg), 58.5% (12.5 mg), 66.5% (25 mg) vs. 32.5% (placebo). There\u00a0are no clinically\u00a0significant\u00a0differences in side effects between the almotriptan-treated patients at doses of 2 mg, 6.25 mg, and 12.5 mg compared with placebo. The study recommends a dose of 12.5 mg to treat migraines because the risk-to-benefit ratio is optimal at this dose, and the 6.25 mg dose demonstrated a minimum effective dose. [7]", "contents": "Almotriptan -- Indications. A randomized double-blinded study by Dalof C. et al examined the therapeutic efficacy and side effect profile of almotriptan.\u00a0The triptan was given as a single dose of 2 mg, 6.25 mg, 12.5 mg, or 25 mg, and it was compared with a placebo in patients with moderate to severe migraine pain intensity. Seven hundred forty-two patients completed the study out of 903 initially enrolled. Almotriptan was superior to placebo in reducing the migraine pain at doses above 2 mg at 2 hours after dose, ie, 30% (2 mg), 56.3% (6.25 mg), 58.5% (12.5 mg), 66.5% (25 mg) vs. 32.5% (placebo). There\u00a0are no clinically\u00a0significant\u00a0differences in side effects between the almotriptan-treated patients at doses of 2 mg, 6.25 mg, and 12.5 mg compared with placebo. The study recommends a dose of 12.5 mg to treat migraines because the risk-to-benefit ratio is optimal at this dose, and the 6.25 mg dose demonstrated a minimum effective dose. [7]"}
{"id": "article-17383_7", "title": "Almotriptan -- Indications", "content": "A double-blind comparison study by Spierings L. et al examined the therapeutic efficacy (24-hour abortive treatment) and side effect profiles of almotriptan vs. sumatriptan, an older anti-migraine medication commonly used in comparison studies. Almotriptan was given at a dose of 12.5 mg, and sumatriptan was given at a dose of 50 mg in patients with moderate to severe migraines. The oral capsules of each medication appeared identical to ensure blinding of patients and investigators. One thousand one hundred seventy-three patients received either almotriptan (591) or sumatriptan (582). Almotriptan was similar to sumatriptan in reducing migraine pain by 58.0% vs. 57.3% respectively.", "contents": "Almotriptan -- Indications. A double-blind comparison study by Spierings L. et al examined the therapeutic efficacy (24-hour abortive treatment) and side effect profiles of almotriptan vs. sumatriptan, an older anti-migraine medication commonly used in comparison studies. Almotriptan was given at a dose of 12.5 mg, and sumatriptan was given at a dose of 50 mg in patients with moderate to severe migraines. The oral capsules of each medication appeared identical to ensure blinding of patients and investigators. One thousand one hundred seventy-three patients received either almotriptan (591) or sumatriptan (582). Almotriptan was similar to sumatriptan in reducing migraine pain by 58.0% vs. 57.3% respectively."}
{"id": "article-17383_8", "title": "Almotriptan -- Indications", "content": "Patients in the almotriptan treatment arm took rescue medications at 36.7% and 33.2% in the sumatriptan treatment arm. Moderate to severe intensity migraines returned in almotriptan and sumatriptan-treated patients at 27.4% vs. 24.0%, respectively. Side effects appeared in 15.2% of almotriptan-treated patients and 19.4% of sumatriptan-treated patients. A potentially significant side effect of chest pain occurred at a higher rate in sumatriptan-treated patients vs. almotriptan-treated patients, 2.2% vs. 0.3%, respectively. The study concluded that almotriptan was similar to sumatriptan in therapeutic efficacy and side effect profiles. [8]", "contents": "Almotriptan -- Indications. Patients in the almotriptan treatment arm took rescue medications at 36.7% and 33.2% in the sumatriptan treatment arm. Moderate to severe intensity migraines returned in almotriptan and sumatriptan-treated patients at 27.4% vs. 24.0%, respectively. Side effects appeared in 15.2% of almotriptan-treated patients and 19.4% of sumatriptan-treated patients. A potentially significant side effect of chest pain occurred at a higher rate in sumatriptan-treated patients vs. almotriptan-treated patients, 2.2% vs. 0.3%, respectively. The study concluded that almotriptan was similar to sumatriptan in therapeutic efficacy and side effect profiles. [8]"}
{"id": "article-17383_9", "title": "Almotriptan -- Indications", "content": "In pregnant women with migraines or headaches, triptan use is less frequent, whereas drugs like metoclopramide and acetaminophen are common choices for migraines due to their effectiveness and safety. [9] Triptans\u00a0are effective in treating menstrual migraines in premenopausal women. Various studies have shown that rizatriptan\u00a0is\u00a0the most beneficial triptan to treat acute menstrual migraines in females. [10] A randomized, placebo-controlled study showed that rizatriptan provided pain relief between 2 and 24 hours with an efficacy of 63% compared to other triptans. [10]", "contents": "Almotriptan -- Indications. In pregnant women with migraines or headaches, triptan use is less frequent, whereas drugs like metoclopramide and acetaminophen are common choices for migraines due to their effectiveness and safety. [9] Triptans\u00a0are effective in treating menstrual migraines in premenopausal women. Various studies have shown that rizatriptan\u00a0is\u00a0the most beneficial triptan to treat acute menstrual migraines in females. [10] A randomized, placebo-controlled study showed that rizatriptan provided pain relief between 2 and 24 hours with an efficacy of 63% compared to other triptans. [10]"}
{"id": "article-17383_10", "title": "Almotriptan -- Indications", "content": "There is limited data on the use of almotriptan during breastfeeding. The concentration of almotriptan in breast milk\u00a0is\u00a0low. Clinicians should consider alternative treatment because of a lack of data on safety. [11] Almotriptan has been used for acute migraines for over 20 years with safety and efficacy. [12] The drug\u00a0is also effective in treating menstrual migraines.", "contents": "Almotriptan -- Indications. There is limited data on the use of almotriptan during breastfeeding. The concentration of almotriptan in breast milk\u00a0is\u00a0low. Clinicians should consider alternative treatment because of a lack of data on safety. [11] Almotriptan has been used for acute migraines for over 20 years with safety and efficacy. [12] The drug\u00a0is also effective in treating menstrual migraines."}
{"id": "article-17383_11", "title": "Almotriptan -- Indications", "content": "Triptans (sumatriptan, zolmitriptan, eletriptan, naratriptan, almotriptan, rizatriptan, and frovatriptan) were studied in 186 randomized controlled trials (N = 101,276). [13] Triptans controlled pain at 2 hours and 1 day when compared to a placebo. Triptans were also a risk for mild and transient side effects.", "contents": "Almotriptan -- Indications. Triptans (sumatriptan, zolmitriptan, eletriptan, naratriptan, almotriptan, rizatriptan, and frovatriptan) were studied in 186 randomized controlled trials (N = 101,276). [13] Triptans controlled pain at 2 hours and 1 day when compared to a placebo. Triptans were also a risk for mild and transient side effects."}
{"id": "article-17383_12", "title": "Almotriptan -- Mechanism of Action -- Mechanism of Action", "content": "Almotriptan is a selective serotonin agonist on the 5-HT1B and 5-HT1D receptors in the cranial arteries. Activation of the 5HT receptors is associated with reducing neurogenic inflammation, which researchers hypothesize to be involved in the migraine relief process.", "contents": "Almotriptan -- Mechanism of Action -- Mechanism of Action. Almotriptan is a selective serotonin agonist on the 5-HT1B and 5-HT1D receptors in the cranial arteries. Activation of the 5HT receptors is associated with reducing neurogenic inflammation, which researchers hypothesize to be involved in the migraine relief process."}
{"id": "article-17383_13", "title": "Almotriptan -- Mechanism of Action -- Pharmacokinetics", "content": "Almotriptan narrows the brain's blood vessels, reduces cerebral blood flow, and reduces\u00a0the transmission of pain signals to the brain. [14]", "contents": "Almotriptan -- Mechanism of Action -- Pharmacokinetics. Almotriptan narrows the brain's blood vessels, reduces cerebral blood flow, and reduces\u00a0the transmission of pain signals to the brain. [14]"}
{"id": "article-17383_14", "title": "Almotriptan -- Mechanism of Action -- Absorption", "content": "The drug has a relatively short half-life of 3 hours, and the oral bioavailability was 69.1%. [15] The currently available oral delivery system of almotriptan has limited bioavailability because of poor aqueous solubility. To improve the solubility of almotriptan, researchers have created a buccal delivery system for almotriptan, which was tested in a rabbit model. [16] The buccal delivery system demonstrated greater absorption when compared to the current oral delivery system", "contents": "Almotriptan -- Mechanism of Action -- Absorption. The drug has a relatively short half-life of 3 hours, and the oral bioavailability was 69.1%. [15] The currently available oral delivery system of almotriptan has limited bioavailability because of poor aqueous solubility. To improve the solubility of almotriptan, researchers have created a buccal delivery system for almotriptan, which was tested in a rabbit model. [16] The buccal delivery system demonstrated greater absorption when compared to the current oral delivery system"}
{"id": "article-17383_15", "title": "Almotriptan -- Mechanism of Action -- Distribution, Metabolism, Elimination", "content": "Almotriptan is excreted in the urine and metabolized predominantly by the cytochrome CYP450 system. [15] Compared with earlier generation triptans such as sumatriptan, almotriptan has a higher oral bioavailability and a shorter plasma half-life. [14]", "contents": "Almotriptan -- Mechanism of Action -- Distribution, Metabolism, Elimination. Almotriptan is excreted in the urine and metabolized predominantly by the cytochrome CYP450 system. [15] Compared with earlier generation triptans such as sumatriptan, almotriptan has a higher oral bioavailability and a shorter plasma half-life. [14]"}
{"id": "article-17383_16", "title": "Almotriptan -- Administration -- Adult Dosage", "content": "The recommended oral dose of almotriptan is 12.5 mg to treat acute migraine attacks in adults and adolescents effectively. [15] The dose may be repeated after\u00a02 hours if a headache returns. More than 2 doses or 25 mg/d is not recommended. Studies have also shown that almotriptan has a synergistic effect when combined with aceclofenac 100 mg to treat an acute migraine attack. [3] Food intake does not affect the absorption of almotriptan. [15]", "contents": "Almotriptan -- Administration -- Adult Dosage. The recommended oral dose of almotriptan is 12.5 mg to treat acute migraine attacks in adults and adolescents effectively. [15] The dose may be repeated after\u00a02 hours if a headache returns. More than 2 doses or 25 mg/d is not recommended. Studies have also shown that almotriptan has a synergistic effect when combined with aceclofenac 100 mg to treat an acute migraine attack. [3] Food intake does not affect the absorption of almotriptan. [15]"}
{"id": "article-17383_17", "title": "Almotriptan -- Administration -- Renal Impairment", "content": "Dosing adjustment is recommended in patients with renal insufficiency.", "contents": "Almotriptan -- Administration -- Renal Impairment. Dosing adjustment is recommended in patients with renal insufficiency."}
{"id": "article-17383_18", "title": "Almotriptan -- Administration -- Hepatic Impairment", "content": "Dosing adjustment is necessary when the drug is used with cytochrome P450 inducers (eg, phenytoin, phenobarbital) and cytochrome P450 inhibitors (eg, certain antimicrobials, grapefruit juice, ketoconazole, protease inhibitors).", "contents": "Almotriptan -- Administration -- Hepatic Impairment. Dosing adjustment is necessary when the drug is used with cytochrome P450 inducers (eg, phenytoin, phenobarbital) and cytochrome P450 inhibitors (eg, certain antimicrobials, grapefruit juice, ketoconazole, protease inhibitors)."}
{"id": "article-17383_19", "title": "Almotriptan -- Adverse Effects", "content": "The common adverse effects of almotriptan are drowsiness, dizziness, headache, nausea, vomiting, chest pain, and fatigue. [17] The drug is associated with a similar incidence of nausea or vomiting compared to other classes of triptans (eg, sumatriptan). However, it shows a decreased incidence of common adverse effects, especially compared to first-generation triptans. [14] [17]", "contents": "Almotriptan -- Adverse Effects. The common adverse effects of almotriptan are drowsiness, dizziness, headache, nausea, vomiting, chest pain, and fatigue. [17] The drug is associated with a similar incidence of nausea or vomiting compared to other classes of triptans (eg, sumatriptan). However, it shows a decreased incidence of common adverse effects, especially compared to first-generation triptans. [14] [17]"}
{"id": "article-17383_20", "title": "Almotriptan -- Adverse Effects", "content": "Almotriptan\u00a0binds to 5HT1B receptors, which are present in the coronary arteries. The administration may result in coronary artery narrowing or spasms, leading to potential coronary artery vasospasm or myocardial infarction. [18] Some rare side effects of almotriptan include pulmonary vasoconstriction, serotonin syndrome, and inhibition of trigeminal nerves. [19] [20]", "contents": "Almotriptan -- Adverse Effects. Almotriptan\u00a0binds to 5HT1B receptors, which are present in the coronary arteries. The administration may result in coronary artery narrowing or spasms, leading to potential coronary artery vasospasm or myocardial infarction. [18] Some rare side effects of almotriptan include pulmonary vasoconstriction, serotonin syndrome, and inhibition of trigeminal nerves. [19] [20]"}
{"id": "article-17383_21", "title": "Almotriptan -- Contraindications -- Box Warnings", "content": "Almotriptan is contraindicated in patients with renal dysfunction or insufficiency and with advanced age due to a physiological decrease in renal function and renal clearance with advanced age. [15]", "contents": "Almotriptan -- Contraindications -- Box Warnings. Almotriptan is contraindicated in patients with renal dysfunction or insufficiency and with advanced age due to a physiological decrease in renal function and renal clearance with advanced age. [15]"}
{"id": "article-17383_22", "title": "Almotriptan -- Contraindications -- Box Warnings", "content": "Minor almotriptan clearance occurs through the CYP450 system (specifically, CYP3A4); therefore, the clinician should avoid other drugs metabolized through this pathway because they may decrease almotriptan clearance. These drugs include but are not limited to verapamil, nifedipine, losartan, cyclosporine, and moclobemide. [15] Patients with\u00a0reduced enzyme activity should be cautious in dosing the drug.", "contents": "Almotriptan -- Contraindications -- Box Warnings. Minor almotriptan clearance occurs through the CYP450 system (specifically, CYP3A4); therefore, the clinician should avoid other drugs metabolized through this pathway because they may decrease almotriptan clearance. These drugs include but are not limited to verapamil, nifedipine, losartan, cyclosporine, and moclobemide. [15] Patients with\u00a0reduced enzyme activity should be cautious in dosing the drug."}
{"id": "article-17383_23", "title": "Almotriptan -- Contraindications -- Warnings and Precautions", "content": "Contraindications to almotriptan include patients with underlying cardiovascular disease\u00a0due to the presence of 5HT1B receptors in the coronary arteries. Almotriptan potentially\u00a0binds to such receptors, further narrowing the arteries or spasms. [18] Patients with hypersensitivity to almotriptan should not use the drug, nor should patients with a history of a hemiplegic or basilar migraine or a heart condition. Moreover, this medication is not used in patients with cerebrovascular syndromes, peripheral vascular disease, or high blood pressure. Caution is necessary if dosing almotriptan within 24 hours of using a serotonin agonist or an ergotamine class medication due to the vasoconstrictive effects of both drugs. [20]", "contents": "Almotriptan -- Contraindications -- Warnings and Precautions. Contraindications to almotriptan include patients with underlying cardiovascular disease\u00a0due to the presence of 5HT1B receptors in the coronary arteries. Almotriptan potentially\u00a0binds to such receptors, further narrowing the arteries or spasms. [18] Patients with hypersensitivity to almotriptan should not use the drug, nor should patients with a history of a hemiplegic or basilar migraine or a heart condition. Moreover, this medication is not used in patients with cerebrovascular syndromes, peripheral vascular disease, or high blood pressure. Caution is necessary if dosing almotriptan within 24 hours of using a serotonin agonist or an ergotamine class medication due to the vasoconstrictive effects of both drugs. [20]"}
{"id": "article-17383_24", "title": "Almotriptan -- Monitoring", "content": "Patients\u00a0prescribed almotriptan should be monitored for the presence of side effects and response to therapy. Kidney function should be monitored when taking the drug as renal clearance may affect the overall drug clearance from the body, causing toxicity. Regular blood pressure monitoring should occur at each clinical visit due to the narrowing effect of the 5-HT1B receptors on the blood vessels\u00a0to assess the drug's effectiveness. [20]", "contents": "Almotriptan -- Monitoring. Patients\u00a0prescribed almotriptan should be monitored for the presence of side effects and response to therapy. Kidney function should be monitored when taking the drug as renal clearance may affect the overall drug clearance from the body, causing toxicity. Regular blood pressure monitoring should occur at each clinical visit due to the narrowing effect of the 5-HT1B receptors on the blood vessels\u00a0to assess the drug's effectiveness. [20]"}
{"id": "article-17383_25", "title": "Almotriptan -- Toxicity", "content": "There are no associated toxicities with almotriptan due to the limited data, although studies demonstrate increased preterm birth rates in pregnant women who\u00a0were prescribed\u00a0triptans for migraine relief. [21]", "contents": "Almotriptan -- Toxicity. There are no associated toxicities with almotriptan due to the limited data, although studies demonstrate increased preterm birth rates in pregnant women who\u00a0were prescribed\u00a0triptans for migraine relief. [21]"}
{"id": "article-17383_26", "title": "Almotriptan -- Toxicity", "content": "An analysis of several case reports of patients undergoing dual triptan-SSRI/SNRI, eg, fluoxetine and venlafaxine therapy or triptan monotherapy, suggested adding\u00a0triptans to SSRI/SNRI therapy does not necessarily increase patients' risk of developing serotonin syndrome. However,\u00a0clinicians should remain cautious and vigilant of the symptoms. [22]", "contents": "Almotriptan -- Toxicity. An analysis of several case reports of patients undergoing dual triptan-SSRI/SNRI, eg, fluoxetine and venlafaxine therapy or triptan monotherapy, suggested adding\u00a0triptans to SSRI/SNRI therapy does not necessarily increase patients' risk of developing serotonin syndrome. However,\u00a0clinicians should remain cautious and vigilant of the symptoms. [22]"}
{"id": "article-17383_27", "title": "Almotriptan -- Enhancing Healthcare Team Outcomes", "content": "Managing the administration of almotriptan in patients with acute migraines requires an interprofessional team of healthcare professionals that includes a neurologist, primary care clinician, nephrologist\u00a0if there is compromised renal function, psychiatrist, specialty-trained nursing staff, and pharmacist for appropriate dosing and safety precautions, working collaboratively to ensure optimal patient outcomes.", "contents": "Almotriptan -- Enhancing Healthcare Team Outcomes. Managing the administration of almotriptan in patients with acute migraines requires an interprofessional team of healthcare professionals that includes a neurologist, primary care clinician, nephrologist\u00a0if there is compromised renal function, psychiatrist, specialty-trained nursing staff, and pharmacist for appropriate dosing and safety precautions, working collaboratively to ensure optimal patient outcomes."}
{"id": "article-17383_28", "title": "Almotriptan -- Enhancing Healthcare Team Outcomes", "content": "Nurses must be ready to inform the prescriber of any potential adverse events from the medication and monitor whether almotriptan provides adequate relief for migraine pain. The pharmacist must look into possible drug-drug interactions, verify dosing, counsel the patient on proper administration, and answer patient questions regarding the safe use of the drug. A robust support system of the patient's family and friends may also\u00a0contribute to successful health outcomes.", "contents": "Almotriptan -- Enhancing Healthcare Team Outcomes. Nurses must be ready to inform the prescriber of any potential adverse events from the medication and monitor whether almotriptan provides adequate relief for migraine pain. The pharmacist must look into possible drug-drug interactions, verify dosing, counsel the patient on proper administration, and answer patient questions regarding the safe use of the drug. A robust support system of the patient's family and friends may also\u00a0contribute to successful health outcomes."}
{"id": "article-17383_29", "title": "Almotriptan -- Enhancing Healthcare Team Outcomes", "content": "Consistent patient follow-up and adherence to appointment times are essential for properly monitoring vital signs and managing any adverse effects. This interprofessional team effort is necessary to optimize therapy with almotriptan so the patient can achieve the best outcomes.", "contents": "Almotriptan -- Enhancing Healthcare Team Outcomes. Consistent patient follow-up and adherence to appointment times are essential for properly monitoring vital signs and managing any adverse effects. This interprofessional team effort is necessary to optimize therapy with almotriptan so the patient can achieve the best outcomes."}
{"id": "article-17383_30", "title": "Almotriptan -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Almotriptan -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}